SOURCE: Benda Pharmaceutical Inc

September 18, 2007 09:15 ET

Benda Unveils Dramatically Enhanced Gendicine® Distribution System, Provides Update on Number of Patients Treated to Date

HUBEI PROVINCE, CHINA--(Marketwire - September 18, 2007) - Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer, has unveiled the dramatic improvements to its Gendicine® distribution system that resulted in Benda subsidiary SiBiono's recently reported 128% quarter on quarter revenue increase. The Company also provides the following information on the approximate number of patients benefiting from Gendicine®:

--  Total patients treated in Q2 '07: 2,000
--  Foreign patients treated in Q2 '07: 130
--  Total patients treated to date (since 2003): 8,700
--  Foreign patients treated to date (since 2003): 1,800
    

Shenzhen SiBiono Gene Tech Co., Ltd, ("SiBiono"), founded in 1998, is a worldwide pioneer in gene therapy development. Its flagship product Gendicine® is the world's first and only approved and commercialized gene therapy medicine. In early April 2007, Benda acquired the majority stake of SiBiono. Following the acquisition, Benda's management team immediately overhauled SiBiono's marketing and sales strategy and grew revenue to approximately $1.5 MM for the three months ended June 30, 2007, compared to approximately $661,482 for the three months ended March 31, 2007 -- a 128% increase.

Before Benda assumed control of the company, SiBiono's distribution system consisted of two salesmen directly marketing Gendicine® to Chinese hospitals. In the brief months following the acquisition, Benda has built a multi-layered and intensive marketing and sales strategy for SiBiono. The new strategy is carried out by a field sales team composed of 17 experienced professionals, many of whom have strong medical backgrounds.

SiBiono's new sales team employs a combination of "push" and "pull" tactics. Under the push tactic, the experienced sales team promotes Gendicine® to large Chinese pharmaceutical firms which have extensive distribution networks and are able to resell Gendicine® to Tier I Chinese hospitals. There are three levels of hospitals in China, ranked according to the level of medical services provided. There are approximately 775 Tier I hospitals in China.

Three months following the Benda's acquisition of SiBiono, the new sales team had successfully entered into resale relationships with over 30 leading Chinese pharmaceutical firms.

Under the pull tactic, those sales people with strong medical backgrounds travel throughout the country and conduct training sessions for doctors in Chinese Tier I hospitals on the applications of Gendicine®. Three months following Benda's acquisition of SiBiono, the new sales team had conducted 15 sessions, training over 2,000 doctors from 400 hospitals. Those doctors, with a full understanding of Gendicine®'s merits and application methods, can now recommend Gendicine® to their cancer patients. During the three months ended June 30, 2007, over 2,000 patients, including 130 foreigner patients, were treated with Gendicine®. By way of comparison, the average quarterly number of patients treated prior to Benda's acquisition was 515; the 2,000 patients treated in the second quarter represents a 288% increase under Benda's leadership.

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (www.bendapharma.com), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information